CRISPR Therapeutics (CRSP) CEO Kulkarni Sells $2.4M of Stock

Chief Executive Officer Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics AG on October 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at a price of $49.78 each, bringing the total transaction value to roughly $2.38 million. This move follows an earlier sale by the same executive on October 14, when he sold 4,098 shares for $201,867.48. The trade was executed directly, leaving him with 311,899 shares after the sale, which marks a 13.3% reduction in his personal holding.

CRSP CRISPR Therapeutics AG

$49.88 ▼ -7.23% year to date

1M 3M YTD

Daily close · Oct 20, 2026

Inside Samarth Kulkarni's CRISPR Therapeutics Trade

The transaction took place at a single reported price of $49.78 per share, slightly below the stock's closing price of $50.04 on October 19, 2026. This sale was not executed under a pre-arranged Rule 10b5-1 trading plan. Following this latest disposal, Kulkarni's remaining stake stands at 311,899 shares.

Other Institutional Activity in CRISPR Therapeutics

Large funds adjusted their positions earlier in the year. ARK Investment Management, LLC trimmed its holdings by 1,853,267 shares, ending the period with 9,460,939 shares valued at about $471.91 million. Orbis Allan Gray Ltd reduced its stake by 657,026 shares to hold 5,449,161 shares worth approximately $271.80 million. GSK plc kept its position steady at 3,220,627 shares valued at roughly $160.64 million. SR One Capital Management, LP also maintained its holdings at 2,038,763 shares worth about $101.69 million. Two Sigma Investments, LP grew its holdings by 505,572 shares, ending with 1,988,621 shares worth roughly $99.19 million.

CRISPR Therapeutics AG Stock Down 0.3%

The stock recently traded around $49.88 as of October 20, 2026, sitting below its 50-day moving average of $54.87 and its 200-day moving average of $53.10. The shares closed at $50.04 on the day of the executive's trade. The equity has traded in a 52-week range between $44.12 and $75.06.

Recent Earnings

The company reported trailing twelve-month revenue of $13.39 million alongside an earnings per share loss of $4.74. The firm posted a return on equity of -26.1%. The next earnings report is scheduled for November 9, 2026.

Insider Buying and Selling at CRISPR Therapeutics AG

Insider activity has included several transactions in recent weeks. On October 6, General Counsel James R. Kasinger sold 1,990 shares for $119,481. On that same day, Kulkarni sold 4,098 shares for $201,867.48, and General Counsel James R. Kasinger sold 1,040 shares for $51,230.40.

Analysts Set New Price Targets

Wall Street coverage features several recent updates from major financial firms. On August 4, 2026, Citigroup maintained its buy rating while raising its price target from $82.00 to $88.00. Citizens reiterated its market outperform rating with an 80.00 dollar target on August 25 and again on August 31. Needham also reiterated a buy rating with an 82.00 dollar target on August 31. More recently, UBS initiated coverage on October 15, 2026, with a neutral rating and a 52.00 dollar target. Overall, the stock carries a consensus buy recommendation from 19 analysts with a mean price target of $85.63.

About CRISPR Therapeutics

Headquartered in Zug, Switzerland, CRISPR Therapeutics AG operates as a biotechnology company focused on developing gene-based medicines for serious human diseases. It utilizes its proprietary gene editing platform to precisely alter specific sequences of genomic DNA.

Bottom Line

Investors will look toward the company's upcoming earnings release on November 9, 2026, for updates on its clinical pipeline and financial status. Monitoring further Form 4 filings will show whether executive selling continues ahead of that date.